Jim Cramer on Tempus AI: “It’s a Decent Spec, I Would Hold on to Some, But Not All”

Group 1 - Tempus AI, Inc. (NYSE:TEM) is recognized for its technology that organizes and analyzes clinical and molecular data to enhance personalized patient care [3] - The company's platform utilizes AI for diagnostic tests, matching patients with clinical trials, and aiding pharmaceutical companies in cancer treatment discovery [3] - Jim Cramer expressed a cautious outlook on TEM, indicating it is a high multiple stock in a sell-off influenced by oil prices and interest rates, suggesting it will continue to decline [1][2] Group 2 - There is a belief that while TEM has potential, other AI stocks may offer better upside potential with less downside risk [4] - The report suggests looking for undervalued AI stocks that could benefit from trends such as Trump-era tariffs and onshoring [4]